Zenas BioPharma Alternatives & Competitors

12 companies similar to Zenas BioPharma — Enabling patients with autoimmune diseases to reimagine life

Mozart Therapeutics, Inc.

Orchestrating the Immune System

36 Series A $80.00M

Seattle, United States

Biotechnology

Nkarta, Inc.

A New Way Forward for Autoimmune Disease

157 Post Ipo Equity $595.00M

South San Francisco, Unit...

Biotechnology Health Care

Repertoire Immune Medicines

Repertoire is a biotechnology company creating a new category of immune medicines for canc...

86 Series B $189.00M

Cambridge, United States

Biotechnology Health and Wellness +1

Dianthus Therapeutics, Inc.

Building a leading biotech company focused in severe autoimmune diseases.

124 Post Ipo Equity $351.50M

United States

Biopharma Biotechnology +1

Track all Zenas BioPharma competitors

Get real-time alerts when any of these companies raise funding, hire, or show growth signals.

See how it works

Adicet Bio, Inc

A biotechnology company discovering and developing first-in-class allogeneic gamma delta C...

124 IPO $408.49M

Redwood City, United Stat...

Biopharma Biotechnology +1

Roivant

Reinventing Biopharma

244 Unknown $5.01B

New York, United States

Biopharma Biotechnology +2

Granza Bio

Reprogramming Immunity for Target-Specific Medicines

7 Seed $7.64M

Biopharma Biotechnology +1

Replicate Bioscience, Inc.

The Power of RNA Amplified

22 Series A $46.00M

San Diego, United States

Biotechnology

Cartesian Therapeutics

Cartesian | Developing potent, safer cell and gene therapies for cancer and autoimmune dis...

4 IPO $132.00M

Biotechnology

Compare

GlycoEra AG

Advancing Glycan Mediated Therapy

30 Series B $179.00M

Wadenswil, Switzerland

Biotechnology Health Care

Sitryx

Harnessing the power of cell metabolism to develop groundbreaking disease-modifying therap...

48 Series A $79.00M

Oxford, United Kingdom

Biotechnology Health Care +1

Autolus Therapeutics

Focused on the development of precisely targeted, controlled & highly active T cell therap...

763 Post Ipo Equity $1.07B

London, United Kingdom

Biopharma Biotechnology +1

About Zenas BioPharma

Enabling patients with autoimmune diseases to reimagine life

Services

Development of therapies for autoimmune diseases, Clinical trial management, Drug research and development, Commercialization of new therapies

Target Customers

Patients with autoimmune diseases, Healthcare providers, Caregivers, Pharmaceutical investors

Taxonomy

Biopharmaceuticals, Autoimmune Diseases, Clinical-stage, Transformative Therapies, Monoclonal Antibody, BTK Inhibitor, CNS-penetrant, Small Molecule, Subcutaneous Injection, B Cell Lineage, Immunology, Macrophage Modulation, Microglial Cells, IL-17 Inhibitor, TYK2 Inhibitor

Business Model

B2B

Revenue Model

Product Sales, Licensing

Frequently Asked Questions

Top alternatives to Zenas BioPharma include Mozart Therapeutics, Inc., Nkarta, Inc., Repertoire Immune Medicines, Dianthus Therapeutics, Inc., Adicet Bio, Inc. These companies serve similar markets and are frequently compared.

Bounce Watch tracks 12 companies similar to Zenas BioPharma based on industry overlap, target customers, and business model.

Enabling patients with autoimmune diseases to reimagine life

Don't just read about them. Follow them.

BounceWatch watches Zenas BioPharma and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.

See how it works

Explore Related

Zenas BioPharma Profile Mozart Therapeutics, Inc. Alternatives Nkarta, Inc. Alternatives Repertoire Immune Medicines Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at Zenas BioPharma on 9 Jun 2026. The 12 companies listed here were last checked between 28 Jan 2026 and 22 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.